![PTC Therapeutics](https://trials-media.s3.amazonaws.com/orgs/ptc-therapeutics.jpeg)
Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of DMD in approximately 10-15% of boys with the disease. Ataluren is an orally-delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 2a extension trial that will evaluate the long-term safety of ataluren in boys with nonsense mutation DMD, as determined by adverse events and laboratory abnormalities. The study will also assess changes in walking, muscle function, strength, and other important clinical and laboratory measures.
![Sarepta Therapeutics, Inc.](https://trials-media.s3.amazonaws.com/orgs/sarepta-therapeutics-inc.jpeg)
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy...
Duchenne Muscular DystrophyThe main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
![Hacettepe University](https://trials-media.s3.amazonaws.com/orgs/hacettepe-university.jpeg)
Neuropsychological Profiles of Children With Duchenne Muscular Dystrophy and Its Effects on Motor...
Duchenne Muscular DystrophyThis study was planned to determine neuropsychological profiles of children with Duchenne Muscular Dystrophy and investigation of its effects on motor functions & compare to typically developed peers.
![BioMarin Pharmaceutical](https://trials-media.s3.amazonaws.com/orgs/biomarin-pharmaceutical.jpeg)
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular DystrophyThe purpose of the study is to see whether BMN053 is safe and effective to use as medication for Duchenne muscular dystrophy (DMD) patients with a mutation around location 53 in the DNA for the dystrophin protein.
![Pfizer](https://trials-media.s3.amazonaws.com/orgs/pfizer.jpeg)
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616...
Duchenne Muscular DystrophyThis is a Phase 2 randomized, 2-period, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, efficacy, PK and PD of PF-06252616 administered to ambulatory boys diagnosed with Duchenne Muscular Dystrophy. Three intravenous (IV) dose levels will be investigated in a within subject dose escalating fashion. Subjects will be randomly assigned to 1 of 3 sequence groups for approximately 96 weeks (2 periods of 48 weeks each). In period 1, two of the sequence groups will receive PF-06252616 and one sequence group will receive placebo. In period 2, the placebo group will switch to PF-06252616 and the two remaining sequence groups will either receive placebo or PF-06252616. Efficacy will be based on an observed mean change from baseline on function (4 stair climb) of PF-06252616 as compared to the placebo at the end of period 1. Period 2 provides an opportunity to evaluate PK. Subjects will receive monthly IV infused doses of either PF-06252616 or placebo and will undergo safety evaluations (Laboratory, cardiac monitoring, physical exams, x-ray, MRI), functional evaluations (pulmonary function testing, 4 stair climb, range of motion, strength testing, Northstar Ambulatory Assessment, upper limb functional testing and the six minute walk test), pharmacokinetic testing and pharmacodynamic testing to evaluate changes in muscle volume (MRI).
![BioMarin Pharmaceutical](https://trials-media.s3.amazonaws.com/orgs/biomarin-pharmaceutical.jpeg)
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular DystrophyThe purpose of the study is to see whether PRO045 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA for the dystrophin protein.
![Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA](https://trials-media.s3.amazonaws.com/orgs/acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-and-co-inc-rahway-nj-usa.jpeg)
Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular DystrophyTo evaluate the long-term safety and tolerability of ACE-031 administration in subjects with Duchenne muscular dystrophy (DMD) who participated in Study A031-03. [Note: This study was terminated based on preliminary safety data. Pending further analysis of safety data and discussion with health authorities, a new ACE-031 trial will be planned.]
![PTC Therapeutics](https://trials-media.s3.amazonaws.com/orgs/ptc-therapeutics.jpeg)
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker...
Duchenne Muscular DystrophyBecker Muscular DystrophyDuchenne/Becker muscular dystrophy (DMD/BMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of DMD/BMD in approximately 10-15% of boys with the disease. Ataluren (PTC124) is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 2a trial that enrolled boys with nonsense mutation DMD/BMD who have lost independent mobility due to the disease. This study evaluated the safety and tolerability of ataluren (PTC124) and also evaluated efficacy outcomes in this participant population.
![Akashi Therapeutics](https://trials-media.s3.amazonaws.com/orgs/akashi-therapeutics.jpeg)
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02
Duchenne Muscular DystrophyThis study, HALO-DMD-03, is a follow-on study to HALO-DMD-01 and HALO-DMD-02, and allows continued open-label access to HT-100 for subjects who have completed these studies. HALO-DMD-03 will provide safety and strength and function data on continuous long-term dosing. Data from this study will be used to inform the safety, tolerability, and dose selection for a future trial of HT-100 in boys with Duchenne Muscular Dystrophy (DMD).
![PTC Therapeutics](https://trials-media.s3.amazonaws.com/orgs/ptc-therapeutics.jpeg)
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy...
Muscular DystrophyDuchenne11 moreThe primary objective of this study is to obtain long term safety data of ataluren in male participants with nonsense mutation dystrophinopathy (who participated and completed a previous Phase 3 study of ataluren [PTC124-GD-020-DMD {NCT01826487}]) to augment the overall safety database. Screening and baseline procedures are structured to avoid a gap in treatment between the double-blind study (PTC124-GD-020-DMD) and this extension study. This study may be further extended by amendment until either ataluren becomes commercially available or the clinical development of ataluren in duchenne muscular dystrophy (DMD) is discontinued.